We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis (NVS - Free Report) announced that it is planning to acquire France-based Advanced Accelerator Applications , a radiopharmaceutical company focused on developing nuclear medicine for a cash offer of $3.9 billion. The company said that it will make an offer for the acquisition upon completion of works council consultation.
The buyout will strengthen Novartis’ presence in cancer space by adding Advanced Accelerator’s RadioLigand Therapy (“RLT”), Lutathera, in its portfolio. The deal will also expand the company’s pipeline into RLT programs, which has significant sales potential for being an innovative approach to treating cancer.
Earlier in September, Lutathera was approved in the EU for treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. It is also under review in the United States for the given indication with a response expected on Jan 26, 2018 from the FDA.
Shares of Novartis have underperformed the industry year to date. The stock has gained 13.5% compared with the industry’s 14.5% rally during the period.
Significantly, Novartis is actively pursuing deals in order to build a long-term portfolio. In the past few years, the company has been seen inking several licensing deals and targets to achieve more on the front in the future.
Earlier, in March 2015, Novartis had acquired certain oncology products and pipeline compounds from GlaxoSmithKline (GSK - Free Report) . In exchange, it sold its non-influenza Vaccines business to Glaxo.
We remind investors that Novartis already has a strong oncology portfolio of drugs like Afinitor, Exjade, Jakavi, Zykadia, Tasigna, Jadenu and an improved formulation of Exjade. Also, the FDA recently approved its breakthrough gene transfer treatment, Kymriah suspension, for treating patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (“ALL”) that is refractory or in second or later relapse. The approval of Kymriah is a major boost to Novartis, given its potential in the CAR T therapy space.
Ligand’s earnings per share estimates have moved up from $3.68 to $3.70 for 2018 over the last 30 days. The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 6.19%. Share price of the company has soared 40.7% year to date.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Novartis Buys French Radiopharmaceutical Company
Novartis (NVS - Free Report) announced that it is planning to acquire France-based Advanced Accelerator Applications , a radiopharmaceutical company focused on developing nuclear medicine for a cash offer of $3.9 billion. The company said that it will make an offer for the acquisition upon completion of works council consultation.
The buyout will strengthen Novartis’ presence in cancer space by adding Advanced Accelerator’s RadioLigand Therapy (“RLT”), Lutathera, in its portfolio. The deal will also expand the company’s pipeline into RLT programs, which has significant sales potential for being an innovative approach to treating cancer.
Earlier in September, Lutathera was approved in the EU for treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. It is also under review in the United States for the given indication with a response expected on Jan 26, 2018 from the FDA.
Shares of Novartis have underperformed the industry year to date. The stock has gained 13.5% compared with the industry’s 14.5% rally during the period.
Significantly, Novartis is actively pursuing deals in order to build a long-term portfolio. In the past few years, the company has been seen inking several licensing deals and targets to achieve more on the front in the future.
Earlier, in March 2015, Novartis had acquired certain oncology products and pipeline compounds from GlaxoSmithKline (GSK - Free Report) . In exchange, it sold its non-influenza Vaccines business to Glaxo.
We remind investors that Novartis already has a strong oncology portfolio of drugs like Afinitor, Exjade, Jakavi, Zykadia, Tasigna, Jadenu and an improved formulation of Exjade. Also, the FDA recently approved its breakthrough gene transfer treatment, Kymriah suspension, for treating patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (“ALL”) that is refractory or in second or later relapse. The approval of Kymriah is a major boost to Novartis, given its potential in the CAR T therapy space.
Novartis AG Price
Novartis AG Price | Novartis AG Quote
Zacks Rank & Stocks to Consider
Novartis currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Ligand Pharmaceuticals Inc. (LGND - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings per share estimates have moved up from $3.68 to $3.70 for 2018 over the last 30 days. The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 6.19%. Share price of the company has soared 40.7% year to date.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>